Judge Dismissed Securities Lawsuit Against Regeneron
A federal ruling clarified that corporate statements on drug enthusiasm are considered puffery, not fraud.
Updated on Sept. 21, 2026 in Public Companies
Live Poll
Should pharmaceutical companies be held legally liable for marketing claims that shape investor expectations?
The U.S. District Court for the Southern District of New York dismissed a proposed class-action securities fraud lawsuit against Regeneron Pharmaceuticals. Investors had alleged the company misrepresented sales performance for its eye treatment drug, Eylea.
Why it matters
This ruling establishes a clear legal boundary for publicly traded firms regarding the difference between material financial disclosures and non-actionable marketing enthusiasm. It underscores the protection companies receive when touting product success, provided the statements do not rise to the level of specific, verifiable financial deceit.
The court dismissed a proposed class-action lawsuit filed against Regeneron Pharmaceuticals regarding its eye treatment drug, Eylea. The ruling effectively clears the firm of investor claims concerning alleged omissions in reporting fee reimbursements to federal regulators.
The players
Regeneron Pharmaceuticals
A biotechnology company that develops and manufactures pharmaceutical products for serious medical conditions.
Mary Kay Vyskocil
A United States District Judge for the Southern District of New York who presides over complex litigation.
The details
Judge Mary Kay Vyskocil ruled that Regeneron's promotional statements regarding Eylea constituted corporate puffery. The court held that companies are entitled to tout the effectiveness and market enthusiasm for their products without disclosing every factor that could influence commercial success. Investors had argued that failing to report credit card fee reimbursements amounted to securities fraud, a claim the court found legally insufficient.
Timeline
September 21, 2026: The court officially dismissed the class-action lawsuit.
Market Landscape
This decision reinforces the established legal standard for corporate puffery in securities litigation. It confirms that pharmaceutical companies maintain broad latitude to promote product efficacy without creating liability for every omitted commercial nuance.
Operators should note that courts remain protective of general corporate enthusiasm, provided statements stay within the bounds of marketing puffery. Maintain clear distinctions between official financial reporting and promotional messaging to mitigate exposure to similar securities litigation.
The takeaway
The court's dismissal reinforces that marketing enthusiasm is not equivalent to financial fraud for publicly traded firms. Business leaders should ensure that any forward-looking sales statements are backed by objective, verifiable data while utilizing puffery for general product branding.
Further reading
For more on regulatory risks and disclosure standards, see our Public Companies coverage.
Live Poll
Should pharmaceutical companies be held legally liable for marketing claims that shape investor expectations?
